Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 66 Earnings Yield (Joel Greenblatt) % is -37.74% as of Jun. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 66/100 and a GF Value™ of kr135.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 86.19% on this metric.
Vitrolife AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr15,104 Mil.
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr-4,776 Mil. Vitrolife AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -37.74%.
The historical rank and industry rank for Vitrolife AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CHIX:VITRs'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -38.77 Med: 2.09 Max: 3.93
Current: -34.97
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Vitrolife AB was 3.93%. The lowest was -38.77%. And the median was 2.09%.
CHIX:VITRs's Earnings Yield (Joel Greenblatt) % is ranked worse than 86.19% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs CHIX:VITRs: -34.97
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vitrolife AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Vitrolife AB (CHIX:VITRs) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vitrolife AB Earnings Yield (Joel Greenblatt) % Related Terms
Vitrolife AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, Vitrolife AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Earnings Yield (Joel Greenblatt) % falls into.
Vitrolife AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vitrolife ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4,776 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -37.74% mean?
Vitrolife AB (CHIX:VITRS) has a Earnings Yield (Joel Greenblatt) % of -37.74% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #730 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 86.2%.
Is Vitrolife AB's Earnings Yield (Joel Greenblatt) % too high?
Vitrolife AB's current Earnings Yield (Joel Greenblatt) % is -37.74%. Based on the distribution chart, Vitrolife AB ranks #730 out of 847 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #730 out of 847 companies for Earnings Yield (Joel Greenblatt) %. This places Vitrolife AB in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.96, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Earnings Yield (Joel Greenblatt) % is -37.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr135.46, compared to a current price of kr86.38 — trading 36.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -37.74%. Vitrolife AB's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Earnings Yield (Joel Greenblatt) % is -37.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 36.2% below its estimated GF Value™ of kr135.46.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
Earnings Yield (Joel Greenblatt) %: -37.74%
GF Value™: kr135.46 vs. price of kr86.38 (36.2% below fair value)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
66GF Score
Get the complete analysis for CHIX:VITRS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
